Viridian Therapeutics Inc (NASDAQ: VRDN) is -40.17% lower on its value in year-to-date trading and has touched a low of $10.93 and a high of $30.30 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VRDN stock was last observed hovering at around $14.25 in the last trading session, with the day’s loss setting it -1.22%.
Currently trading at $13.03, the stock is -18.90% and -25.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing -8.56% at the moment leaves the stock -26.64% off its SMA200. VRDN registered -55.19% loss for a year compared to 6-month gain of 17.18%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -25.75% loss in the last 1 month and extending the period to 3 months gives it a -30.62%, and is -13.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.41% over the week and 5.04% over the month.
Viridian Therapeutics Inc (VRDN) has around 96 employees, a market worth around $817.89M and $0.31M in sales. Profit margin for the company is -75711.46%. Distance from 52-week low is 19.27% and -57.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.32%).
The EPS is expected to grow by 15.57% this year
The shares outstanding are 62.77M, and float is at 55.85M with Short Float at 16.96%.
Viridian Therapeutics Inc (VRDN) Insider Activity
The most recent transaction is an insider purchase by Fairmount Funds Management LLC, the company’s Director. SEC filings show that Fairmount Funds Management LLC bought 476,190 shares of the company’s common stock on Jan 22 ’24 at a price of $21.00 per share for a total of $10.0 million. Following the purchase, the insider now owns 1.84 million shares.
Viridian Therapeutics Inc disclosed in a document filed with the SEC on Jun 16 ’23 that Meisner Lara (Chief Legal Officer) sold a total of 27 shares of the company’s common stock. The trade occurred on Jun 16 ’23 and was made at $28.35 per share for $765.0. Following the transaction, the insider now directly holds 29971.0 shares of the VRDN stock.
Still, SEC filings show that on Jun 15 ’23, Meisner Lara (Chief Legal Officer) disposed off 2,269 shares at an average price of $28.02 for $63577.0. The insider now directly holds 29,971 shares of Viridian Therapeutics Inc (VRDN).
